PRECISION BIOSCIENCES INC
For the period ended Mar 31, 2024. Filed May 13, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 13, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Unregistered Sales of Equity Securities and Use of Proceeds
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.
On February 5, 2024, we issued 97,360 shares of our common stock to TG Therapeutics in exchange for the $2.25 million cash payment comprising part of the TG Upfront Payment that was paid to the Company as partial consideration for the license rights we granted to TG Therapeutics pursuant to the TG License Agreement. The issuance of the shares to TG Therapeutics was not registered under the Securities Act in reliance upon the exemption from registration provided by Section 4(a)(2) thereunder.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.